Compare
Amgen vs Neurocrine Biosciences (AMGN vs NBIX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Neurocrine Biosciences (NBIX) +7.1%; so far this year the figures are +40.7% and +16.1%.
Amgen is the larger company by market value, about 14.9 times the size of Neurocrine Biosciences.
On trailing earnings, AMGN trades at 26.7 times and NBIX at 24.4 times.
Revenue grew +8.2% at AMGN and +38.0% at NBIX over the last year.
AMGN yields 2.16%. NBIX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | NBIX | |
|---|---|---|
| Price | $460.42 | $164.63 |
| 1-day | +0.03% | +3.05% |
| YTD | +40.67% | +16.08% |
| 1 year | +43.94% | +7.08% |
| 3 years | +76.51% | +47.60% |
| Market cap | $249.1B | $16.7B |
| P/E | 26.7 | 24.4 |
| P/S | 6.40 | 4.50 |
| P/B | 17.35 | 4.30 |
| Revenue growth | +8.20% | +38.00% |
| EPS growth | +33.30% | +61.20% |
| Gross margin % | 70.9 | 97.8 |
| Net margin % | 24.1 | 19.0 |
| ROE % | 65.4 | 18.1 |
| Debt / equity | 3.76 | 0.00 |
| FCF yield % | 3.8 | 6.2 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.64 |
| RSI (14) | 60.5 | 69.4 |
| Technical rating |